Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1016/j.vaccine.2020.08.045 http://scihub22266oqcxt.onion/10.1016/j.vaccine.2020.08.045 32863070!7440160!32863070     free     free     free Warning: file_get_contents(https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&id=32863070&cmd=llinks): Failed to open stream: HTTP request failed! HTTP/1.1 429 Too Many Requests in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 215       Vaccine 2020 ; 38 (41): 6352-6356 Nephropedia Template TP {{tp|p=32863070|t=2020. BCG vaccine may generate cross-reactive T cells against SARS-CoV-2: In silico analyses and a hypothesis |pdf=|usr=}}{{32863070}} gab.com Text BCG vaccine may generate cross-reactive T cells against SARS-CoV-2: In silico analyses and a hypothesis JO: Vaccine http://www.kidney.de/pget.php?&tw=1&pmid=32863070 #FOAvip The world is facing the rising emergency of SARS-CoV-2. The outbreak of COVID-19 has caused a global public health and economic crisis.Recent epidemiological studies have shown that a possible association of BCG vaccination program with decreased COVID-19-related risks, suggesting that BCG may provide protection against COVID-19. Non-specific protection against viral infections is considered as a main mechanism of BCG and clinical trials to determine whether BCG vaccine can protect healthcare workers from the COVID-19 are currently underway. We hypothesized that BCG may carry similar T cell epitopes with SARS-CoV-2 and evaluated the hypothesis by utilizing publicly available database and computer algorithms predicting human leukocyte antigen (HLA) class I-binding peptides. We foundthatBCG contains similar 9-amino acid sequences with SARS-CoV-2. These closely-related peptides had moderate to high binding affinity for multiple common HLA class I molecules, suggesting that cross-reactive T cells against SARS-CoV-2 could be generated by BCG vaccination. Twit Text FOAVip BCG vaccine may generate cross-reactive T cells against SARS-CoV-2: In silico analyses and a hypothesis ????Vaccine http://www.kidney.de/pget.php?&tw=1&pmid=32863070 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=32863070 #FOAvip English Wikipedia <ref>{{Cite pmid|32863070}}</ref> BCG vaccine may generate cross-reactive T cells against SARS-CoV-2: In silico analyses and a hypothesis #MMPMID32863070 Tomita Y; Sato R; Ikeda T; Sakagami T Vaccine 2020[Sep]; 38 (41): 6352-6356 PMID32863070show ga The world is facing the rising emergency of SARS-CoV-2. The outbreak of COVID-19 has caused a global public health and economic crisis.Recent epidemiological studies have shown that a possible association of BCG vaccination program with decreased COVID-19-related risks, suggesting that BCG may provide protection against COVID-19. Non-specific protection against viral infections is considered as a main mechanism of BCG and clinical trials to determine whether BCG vaccine can protect healthcare workers from the COVID-19 are currently underway. We hypothesized that BCG may carry similar T cell epitopes with SARS-CoV-2 and evaluated the hypothesis by utilizing publicly available database and computer algorithms predicting human leukocyte antigen (HLA) class I-binding peptides. We foundthatBCG contains similar 9-amino acid sequences with SARS-CoV-2. These closely-related peptides had moderate to high binding affinity for multiple common HLA class I molecules, suggesting that cross-reactive T cells against SARS-CoV-2 could be generated by BCG vaccination. |Amino Acid Sequence/genetics[MESH] |BCG Vaccine/*immunology[MESH] |Betacoronavirus/genetics/*immunology[MESH] |CD8-Positive T-Lymphocytes/*immunology[MESH] |COVID-19[MESH] |Coronavirus Infections/*prevention & control[MESH] |Cross Reactions/immunology[MESH] |Epitopes, T-Lymphocyte/genetics/*immunology[MESH] |Histocompatibility Antigens Class I/immunology[MESH] |Humans[MESH] |Mycobacterium bovis/genetics/immunology[MESH] |Pandemics/*prevention & control[MESH] |Pneumonia, Viral/*prevention & control[MESH] |SARS-CoV-2[MESH]BCG vaccine may generate cross-reactive T cells against SARS-CoV-2: In(epmc).pdf DeepDyve Pubget Overpricing